Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants

被引：24
|
作者：
Vogel, AM
Lennon, DR
Broadbent, R
Byrnes, CA
Grimwood, K
Mildenhall, L
Richardson, V
Rowley, S
机构：
[1] Univ Auckland, Wellington, New Zealand
[2] Paediat Soc New Zealand, Infect Dis & Immunisat Comm, Wellington, New Zealand
[3] Paediat Soc New Zealand, Fetus & Newborn Comm, Wellington, New Zealand
[4] Paediat Soc New Zealand, Resp Comm, Wellington, New Zealand
来源：
JOURNAL OF PAEDIATRICS AND CHILD HEALTH | 2002年 / 38卷 / 06期
关键词：
consensus; cost effectiveness; palivizumab; preterm; respiratory syncytial virus;
D O I：
10.1046/j.1440-1754.2002.00057.x
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Palivizumab prophylaxis significantly reduces hospitalization for respiratory syncytial virus (RSV) disease in preterm infants. However, palivizumab is very expensive. Data from a New Zealand cost-effectiveness analysis were considered by representatives of the Infectious Diseases and Immunisation, Fetus and Newborn, and Respiratory Committees of the Paediatric Society of New Zealand. Prophylaxis in all high-risk groups was associated with net cost. The consensus panel recommends that the priority for palivizumab be given to babies discharged on home oxygen with chronic lung disease, followed by babies born at 28 weeks or less gestation.
引用
收藏
页码：550 / 554
页数：5
相关论文
共 50 条
  • [1] Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants: A note of caution
    Suresh, S
    Schilling, S
    Dakin, C
    Harris, MA
    [J]. JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2003, 39 (08) : 637 - 637
  • [2] Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
    Mejias, Asuncion
    Ramilo, Octavio
    [J]. BIOLOGICS-TARGETS & THERAPY, 2008, 2 (03): : 433 - 439
  • [3] Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: A cost-effectiveness analysis
    Lolfand, JH
    Touch, SM
    O'Connor, JP
    Chatterton, ML
    Moxey, ED
    Paddock, LE
    Nash, DB
    Desai, SA
    [J]. CLINICAL THERAPEUTICS, 2000, 22 (11) : 1357 - 1369
  • [4] Hospital admission of high risk infants for respiratory syncytial virus infection:: implications for palivizumab prophylaxis
    Heikkinen, T
    Valkonen, H
    Lehtonen, L
    Vainionpää, R
    Ruuskanen, O
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 2005, 90 (01): : F64 - F68
  • [5] Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
    Null, D
    Bimle, C
    Weisman, L
    Johnson, K
    Steichen, J
    Singh, S
    Wang, E
    Asztalos, E
    Loeffler, AM
    Azimi, PH
    Lieberman, JM
    O'Donnell, NE
    Cooke, RJ
    McCormick, K
    Koo, W
    Hammami, M
    Milner, AD
    Gaon, P
    Nachman, S
    Tarpey, KP
    Sánchez, PJ
    Broyles, RS
    Bratcher, D
    Ball, MV
    Duda, FJ
    DeCuir, PM
    Pollara, B
    Nelson, LS
    Balbus, M
    Schultz, MJ
    Chipps, BE
    Givner, LB
    O'Shea, M
    Everard, M
    Pfeffer, K
    Page, AJ
    Dennehy, PH
    Modlin, J
    Rhodes, T
    DeVincenzo, N
    Nickerson, B
    Arrieta, A
    Boucher, FD
    Keeney, RE
    Young, TE
    Stevens, JC
    Ariagno, R
    Adams, M
    Polak, MJ
    Lynch, SK
    [J]. PEDIATRICS, 1998, 102 (03) : 531 - 537
  • [6] Nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants
    Ashkenazi-Hoffnung, Liat
    Dotan, Miri
    Livni, Gilat
    Amir, Jacob
    Bilavsky, Efraim
    [J]. AMERICAN JOURNAL OF INFECTION CONTROL, 2014, 42 (09) : 991 - 995
  • [7] Palivizumab for respiratory syncytial virus (RSV) prophylaxis of high-risk infants in a medicaid health maintenance organization (HMO)
    Schaffer, M
    Greenspan, JS
    Amaya, MA
    Vojta, D
    [J]. PEDIATRIC RESEARCH, 2000, 47 (04) : 322A - 322A
  • [8] Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection
    Caserta, Mary T.
    O'Leary, Sean T. R.
    Munoz, Flor M. M.
    Ralston, Shawn L.
    [J]. PEDIATRICS, 2023, 152 (01)
  • [9] Cost-effectiveness analysis of palivizumab for respiratory syncytial virus infection in high-risk infants in Japan
    Ikeda, S.
    Kobayashi, M.
    [J]. VALUE IN HEALTH, 2007, 10 (03) : A170 - A170
  • [10] COST-EFFECTIVENESS ANALYSIS OF PALIVIZUMAB AS A PROPHYLAXIS FOR RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN HIGH-RISK LATE PRETERM INFANTS IN THE NETHERLANDS
    Langenfeld, M. K.
    Visser, S.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A372 - A372
12345